Picture Berlin Partner Hotspot for Startups 650x80px

Product › Details

LentiVector® technology

	Next higher product group	lentiviral vector
	Status	2005-07-04 development p2 existent
	Organisation	Oxford Biomedica plc (LSE: OXB)
	Group	Oxford Biomedica (Group)

Record changed: 2021-04-08

Picture [iito] Made Without Love 650x80px

More documents for LentiVector® technology

[1] Oxford Biomedica plc. (5/6/21). "Press Release: Oxford Biomedica Signs a New Three Year Development & Supply Agreement with Boehringer Ingelheim for the Manufacture and Supply of Viral Vectors". Oxford....
[2] PhoreMost Ltd.. (11/9/20). "Press Release: PhoreMost and Oxford Biomedica Enter Gene Therapy Discovery Collaboration". Cambridge & Oxford....
[3] Oxford Biomedica plc. (3/18/20). "Press Release: Oxford BioMedica Signs License & Clinical Supply Agreement with Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, for LentiVector Platform for CAR-T and TCR-T Therapeutics". Oxford....
[4] Oxford Biomedica plc. (3/18/20). "Press Release: Building the Group for Future Growth. Business Update". Oxford....
[5] Oxford Biomedica plc. (3/14/19). "Press Release: Oxford Biomedica plc Preliminary Results for the Year Ended 31 December 2018". Oxford....
[6] Boehringer Ingelheim. (8/6/18). "Press Release: Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis". Ingelhei...
[7] Oxford Biomedica plc. (6/6/18). "Press Release: Oxford BioMedica and Axovant Sciences Enter into a $842.5 Million Exclusive Worldwide Licence Agreement for OXB-102 for the Treatment of Parkinson’s Disease". Oxford....
[8] Oxford Biomedica plc. (2/15/18). "Press Release: Oxford BioMedica Announces Collaboration and Licence Agreement with Bioverativ in the Field of Haemophilia Gene Therapy". Oxford....
[9] Oxford Biomedica plc. (9/4/17). "Press Release: Oxford BioMedica to Present at Rodman & Renshaw Annual Global Investment Conference, New York". Oxford....
[10] Oxford Biomedica plc. (8/17/17). "Press Release: Interim Results for the Six Months Ended 30 June 2017". Oxford....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]